Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens-Reference-Cited by-同舟云学术

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

Published:2011-12 Issue:12 Volume:52 Page:2299-2303
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Eleftherakis-Papapiakovou Evangelos,Kastritis Esftathios,Roussou Maria,Gkotzamanidou Maria,Grapsa Irini,Psimenou Erasmia,Nikitas Nikitas,Terpos Evangelos,Dimopoulos Meletios A.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.597906

Reference25 articles.

1. Prognostic features in the third MRC myelomatosis trial.

2. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases

3. Renal Failure in Multiple Myeloma

4. Renal Failure in Multiple Myeloma

5. Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Renal Failure in Multiple Myeloma;Recent Updates on Multiple Myeloma;2023-03-15

2. Management of acute kidney injury in symptomatic multiple myeloma;Kidney International;2021-03

3. Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients;Clinical Lymphoma Myeloma and Leukemia;2020-10

4. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant;Transplantation Proceedings;2020-09

5. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma;BMC Cancer;2020-08-24